Can a targeted drug combo outsmart bile duct cancer?
Disease control
Recruiting now
This phase II trial is testing whether combining pemigatinib—a drug that targets FGFR2 mutations—with an immunotherapy drug (a PD-1 inhibitor) and possibly chemotherapy can help people with advanced bile duct cancer that has FGFR2 fusions or rearrangements. The study enrolls adul…
Phase 2 • Sponsor: Haitao Zhao, MD • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC